Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	30,084	24,021	29,238	20,282	15,100	12,840
Market Cap Growth	-24.30%	-17.84%	44.16%	34.32%	17.60%	74.32%
Enterprise Value	29,014	22,887	28,366	18,844	13,747	11,608
PE Ratio	-	-54.56	-25.85	-23.78	-17.59	-14.49
PS Ratio	15.02	13.14	28.18	24.02	30.64	58.43
PB Ratio	-85.84	-108.87	-184.79	34.48	14.86	8.93
P/FCF Ratio	235.35	572.67	-47.67	-28.25	-22.03	-30.68
P/OCF Ratio	159.07	230.62	-54.02	-31.61	-24.55	-46.12
EV/Sales Ratio	14.48	12.52	27.34	22.32	27.89	52.82
EV/EBITDA Ratio	-176.14	-106.32	-32.03	-30.42	-19.73	-13.97
EV/EBIT Ratio	-90.01	-73.28	-29.21	-26.57	-17.83	-13.11
EV/FCF Ratio	226.98	545.63	-46.25	-26.24	-20.06	-27.73
Debt / Equity Ratio	-5.93	-5.92	-8.34	1.70	0.51	0.21
Debt / EBITDA Ratio	-12.91	-6.06	-1.49	-1.61	-0.75	-0.37
Debt / FCF Ratio	10.18	31.12	-2.15	-1.39	-0.76	-0.73
Quick Ratio	2.86	2.86	3.16	3.79	3.38	4.48
Current Ratio	3.17	3.08	3.51	4.04	4.47	4.87
Asset Turnover	0.54	0.51	0.30	0.24	0.16	0.09
Interest Coverage	-1.55	-2.58	-6.23	-4.96	-9.13	-
Return on Equity (ROE)	131.00%	167.10%	-1287.80%	-109.20%	-68.90%	-55.80%
Return on Assets (ROA)	-8.90%	-12.20%	-32.70%	-24.60%	-27.80%	-36.70%
Return on Capital (ROIC)	-16.25%	-26.01%	-67.56%	-44.69%	-53.88%	-53.91%
Earnings Yield	-1.10%	-1.83%	-3.87%	-4.20%	-5.68%	-6.90%
FCF Yield	0.42%	0.17%	-2.10%	-3.54%	-4.54%	-3.26%
Buyback Yield / Dilution	-1.63%	-2.64%	-2.73%	-3.01%	-5.24%	-8.62%
Total Shareholder Return	-1.63%	-2.64%	-2.73%	-3.01%	-5.24%	-8.62%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).